drugset / Trial / NCT03078374

MAGENTUM 1 HeartMate 3 LVAS: A Single Center Prospective Controlled Study (MAGENTUM 1)

NCT03078374

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to obtain single-center safety and feasibility data on patients managed with reduced anti-coagulation, and the incidence of thrombotic and bleeding adverse events associated with the HeartMate 3 LVAS therapy.

Timeline

Start
2017-01-11
Primary completion
2022-01
Completion
2022-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Warfarin Small molecule

Indications